Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Phagelux In-licenses Delivery Systems for Phage-based Products

publication date: Jan 4, 2015
Phagelux, Inc., a Shanghai company that is developing phage-based anti-bacterial products, has in-licensed several biodegradable polymer delivery systems from Iveria Technologies of the US.  Mark Engel, Chairman of Phagelux, told ChinaBio® Today, "The technologies acquired will primarily be used for human health although there are also some potential applications in animal health area, especially pets ." Phages are  potential alternatives to many uses of antibiotics, including drug-resistant bacteria strains. Engel said the Iveria deal contained provisions for upfront payments, milestones and royalties on sales. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital